Anavex Life Sciences (NASDAQ:AVXL) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a research report report published on Monday,Benzinga reports. HC Wainwright currently has a $42.00 price target on the biotechnology company’s stock.

Separately, D. Boral Capital restated a “buy” rating and issued a $46.00 price target on shares of Anavex Life Sciences in a research report on Monday.

Anavex Life Sciences Price Performance

Shares of NASDAQ AVXL opened at $8.72 on Monday. The firm has a market cap of $741.76 million, a price-to-earnings ratio of -15.85 and a beta of 0.80. The stock’s fifty day moving average price is $8.70 and its two-hundred day moving average price is $8.48. Anavex Life Sciences has a one year low of $3.25 and a one year high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last released its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. On average, equities analysts anticipate that Anavex Life Sciences will post -0.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Anavex Life Sciences

A number of hedge funds have recently made changes to their positions in AVXL. Vermillion Wealth Management Inc. bought a new stake in Anavex Life Sciences in the fourth quarter valued at approximately $34,000. Tower Research Capital LLC TRC lifted its position in shares of Anavex Life Sciences by 102.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 1,708 shares during the period. Berkshire Money Management Inc. bought a new stake in shares of Anavex Life Sciences in the 4th quarter valued at $107,000. Prudential Financial Inc. acquired a new stake in shares of Anavex Life Sciences during the fourth quarter worth $109,000. Finally, Fiduciary Alliance LLC acquired a new stake in shares of Anavex Life Sciences during the fourth quarter worth $119,000. 31.55% of the stock is currently owned by institutional investors.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.